2-哌嗪-1-基-1,3-苯并噻唑 | 55745-83-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-哌嗪-1-基-1,3-苯并噻唑
• 中文别名: 2-(1-哌嗪基)苯并噻唑；2-(哌嗪-1-基)苯并噻唑
• 英文名称: 2-piperazinobenzothiazole
• 英文别名: 2-(piperazin-1-yl)-benzothiazole；2-(piperazin-1-yl)benzo[d]thiazole；2-(1-piperazinyl)benzothiazole；1-(1,3-benzothiazol-2-yl)piperazine；2-Piperazin-1-yl-benzothiazole；2-piperazin-1-yl-1,3-benzothiazole
• CAS: 55745-83-0
• 化学式: C₁₁H₁₃N₃S
• mdl: MFCD01417996
• 分子量: 219.31
• InChiKey: LLQMZXMBCQNMJV-UHFFFAOYSA-N

物化性质

• 熔点：
  75-79℃
• 沸点：
  370.5±52.0 °C(Predicted)
• 密度：
  1.256

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  56.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934200090
• WGK Germany：
  3
• 危险性防范说明：
  P264,P270,P301+P312,P330,P501
• 危险性描述：
  H302
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  2-哌嗪-1-基-1,3-苯并噻唑 在 potassium fluoride on basic alumina 、 锌 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 6.33h， 生成 4-(5-(3-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)propylthio)-1,3,4-oxadiazol-2-yl)phenol
  参考文献：
  名称：

  Synthesis of piperazinyl benzothiazole/benzoxazole derivatives coupled with 1,3,4-oxadiazole-2-thiol: novel hybrid heterocycles as anticancer agents

  摘要：

  The synthesis of a series of substituted 2-(piperazin-1-yl)benzothiazole/benzoxazole coupled with 1,3,4-oxadiazole-2-thiol pharmacophore (8a-t) is described using a three carbon spacer (Jones and Helm, Drugs 69:1903-1910, 2009). The structures of the compounds were confirmed by NMR and mass spectral data. All the synthesized compounds have been evaluated for their cytotoxicity towards five human cancer cell lines of different origins, viz. MCF-7 (Breast), HeLa (Cervical), HepG(2) (Liver), A431 (Skin) and A549 (Lung), and IC50 values were determined. Among the compounds tested, 8j and 8t displayed maximum cytotoxic activity. A431 was the most sensitive cell line against the compounds studied, followed by MCF7, A549, HepG(2) and HeLa.

  DOI：

  10.1007/s00044-013-0510-y
• 作为产物：
  描述：

  2-甲硫基苯并噻唑 在 potassium permanganate 、 溶剂黄146 作用下， 反应 6.0h， 生成 2-哌嗪-1-基-1,3-苯并噻唑
  参考文献：
  名称：

  Orjales; Bordell; Rubio, Journal of Heterocyclic Chemistry, 1995, vol. 32, # 3, p. 707 - 718

  摘要：

  DOI：

文献信息

• 2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative Activity
  作者：Lei Wang、Marina Kofler、Gerald Brosch、Jelena Melesina、Wolfgang Sippl、Elisabeth D. Martinez、Johnny Easmon

  DOI：10.1371/journal.pone.0134556

  日期：——

  e ring was replaced by the isosteric heterocycles benzimidazole, benzoxazole, and benzothiazole and the position of the hydroxamic acid substituent on the phenyl ring was varied. Whereas compounds bearing a para substituted hydroxamic acid (9a-d) were active HDAC inhibitors, the meta substituted analogues (8a-d) were appreciably inactive. Compounds 9a-d selectively inhibited HDAC6 (IC50 = 0.1-1.0 μM)

  我们已经在建立的基于细胞的测定法中筛选了我们的化合物集合，该测定法测量表观遗传沉默的转基因的去阻抑，即基因座去阻抑测定。该筛选导致鉴定出4- [4-（1-（甲基苯并咪唑-2-基）哌嗪-1-基]磺酰基苯碳氧肟酸（9b）作为抑制HDAC1的活性物质。在初始结构活性关系研究中，1-甲基苯并咪唑环被等位杂环苯并咪唑，苯并恶唑和苯并噻唑取代，并且异羟肟酸取代基在苯环上的位置也有所变化。带有对位取代的异羟肟酸（9a-d）的化合物是活性HDAC抑制剂，而间位取代的类似物（8a-d）则无活性。与HDAC1（IC50 = 0）相比，化合物9a-d选择性抑制HDAC6（IC50 = 0.1-1.0μM）。而且，与患者匹配的正常细胞相比，也有选择性地抑制了肺癌细胞（9-6μM）的生长。与对照组相比，该化合物在S期诱导细胞周期停滞，而细胞凋亡的诱导则可忽略。分子模型研究发现，9a-d与HDAC6相互作用的MM-G
• Pd-Catalyzed Synthesis of Piperazine Scaffolds Under Aerobic and Solvent-Free Conditions
  作者：Sean W. Reilly、Robert H. Mach

  DOI：10.1021/acs.orglett.6b02591

  日期：2016.10.21

  A facile Pd-catalyzed methodology providing an efficient synthetic route to biologically relevant arylpiperazines under aerobic conditions is reported. Electron donating and sterically hindered aryl chlorides were aminated to afford yields up to 97%, with examples using piperazine as solvent, illustrating an ecofriendly, cost-effective synthesis of these privileged structures.

  据报道，一种简便的钯催化方法为有氧条件下生物相关的芳基哌嗪提供了有效的合成路线。给电子和位阻芳基氯化物被胺化，产率高达 97%，其中使用哌嗪作为溶剂的例子，说明了这些特殊结构的生态友好、经济有效的合成。
• REMEDIES OR PREVENTIVES FOR AIDS
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0878194A1

  公开（公告）日：1998-11-18

  The present invention is to provide the combined use of one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor, and an AIDS therapeutic agent or preventive agent containing as its active ingredients one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor.

  本发明提供了一种或两种或两种以上具有抗HIV活性的喹诺酮羧酸与一种或两种或两种以上的逆转录酶抑制剂或HIV蛋白酶抑制剂的联合使用，以及一种包含作为其活性成分的抗HIV活性的喹诺酮羧酸和一种或两种或两种以上的逆转录酶抑制剂或HIV蛋白酶抑制剂的艾滋病治疗剂或预防剂。
• Non-Imidazole Histamine H3 Ligands, Part 2: New 2-Substituted Benzothiazoles as Histamine H3 Antagonists
  作者：Krzysztof Walczynski、Roman Guryn、Obbe P. Zuiderveld、Henk Timmerman

  DOI：10.1002/(sici)1521-4184(199911)332:11<389::aid-ardp389>3.0.co;2-u

  日期：1999.11

  New, non‐imidazole histamine H3 receptor antagonists were prepared and in vitro tested as H3 receptor antagonists measured as the electrically evoked contraction of the guinea‐pig jejunum. The 2‐(1‐piperidinyl)‐ and 2‐(1‐pyrrolidinyl)benzothiazoles show no or very poor activity; 2‐[1‐(4‐amino)piperidinyl]‐ and 2‐(1,2‐ethanediamino)‐ and 2‐(1,3‐propanediamino)derivatives of benzothiazole possess weak

  制备了新的非咪唑组胺 H3 受体拮抗剂，并作为 H3 受体拮抗剂进行了体外测试，测量结果为豚鼠空肠的电诱发收缩。2- (1-哌啶基) - 和 2- (1- 吡咯烷基) 苯并噻唑没有活性或活性很差；苯并噻唑的 2- [1- (4- 氨基) 哌啶基] - 和 2- (1,2- 乙二氨基) - 和 2- (1,3- 丙二氨基) 衍生物对 H3 受体具有弱活性，而 2- (4-哌啶基) 苯并噻唑和 2-[1- (4-哌嗪基)] 苯并噻唑表现出中等至良好的活性。亲脂性且不太笨重的替代品，如与哌嗪或哌啶环上的氮相连的正丙基，可产生有效的 H3 受体拮抗剂，其 pA2 值范围为 7.0 至 7.2。讨论了不同取代模式的构效关系。
• NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT
  申请人：HYUNDAI PHARM CO., LTD

  公开号：US20160024063A1

  公开（公告）日：2016-01-28

  The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating GPR40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs. That is, the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention can be co-administered with other drugs and can promote the activation of GPR40 protein significantly, so that the composition comprising the same as an active ingredient can be efficiently used as a pharmaceutical composition for the prevention and treatment of metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X, etc.

  本发明涉及一种新型的3-(4-(苄氧基)苯基)己-4-羧酸衍生物，其制备方法以及包含该衍生物作为活性成分的药物组合物，用于预防和治疗代谢性疾病。本发明的这种新型的3-(4-(苄氧基)苯基)己-4-羧酸衍生物、其光学异构体或其药用可接受盐，对于激活GPR40蛋白并相应地促进胰岛素分泌具有优良活性，且在与其他药物联合使用时没有毒性。也就是说，本发明的这种新型的3-(4-(苄氧基)苯基)己-4-羧酸衍生物、其光学异构体或其药用可接受盐，可以与其他药物联合使用，并且能显著促进GPR40蛋白的激活，使得包含其作为活性成分的组合物能有效地用作预防和治疗诸如肥胖、I型糖尿病、II型糖尿病、糖耐量异常、胰岛素抵抗、高血糖、高脂血症、高甘油三酯血症、高胆固醇血症、血脂异常和X综合症等代谢性疾病的药物组合物。